ReproCell Stock

ReproCell Stock-Based Compensation

The Stock-Based Compensation (SBC) of ReproCell (4978.T) as of Sep 4, 2026 is 51.41 M JPY. In the previous year, Stock-Based Compensation (SBC) was 52.19 M JPY — a change of -1.49% (lower).

Stock-Based Compensation

51.41 MJPY

YoY

-1.49%

Last updated:

Stock-Based Compensation (SBC) of ReproCell is 2026 51.41 M JPY. Stock-Based Compensation (SBC) of ReproCell was 2025 52.19 M JPY. It decreases by -1.49% lower compared to the previous year.

The ReproCell Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
25.94 M JPY
Jan 1, 2019
26.44 M JPY
Jan 1, 2020
30.48 M JPY
Jan 1, 2021
28.28 M JPY
Jan 1, 2022
43.64 M JPY
Jan 1, 2023
56.40 M JPY
Jan 1, 2024
52.19 M JPY
Jan 1, 2025
51.41 M JPY
The ReproCell Stock-Based Compensation history
YEARStock-Based CompensationYoY
51.41 MJPY-1.49%
52.19 MJPY-7.46%
56.40 MJPY+29.22%
43.64 MJPY+54.31%
28.28 MJPY-7.21%
30.48 MJPY+15.27%
26.44 MJPY+1.95%
25.94 MJPY+214.53%
8.25 MJPY+3,133.73%
255,000.00JPY-99.72%
90.00 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Stock-Based Compensation (SBC) of ReproCell is 51.41 M JPY in 2026.

Stock-Based Compensation (SBC) of ReproCell changed from 52.19 M JPY to 51.41 M JPY, representing a -1.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) ReproCell since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s ReproCell historically and in real time.

Access this data via the Eulerpool API

Cash Flow — ReproCell

All Key Metrics — ReproCell